Amgen’s T-Cell Engager Shows Phase II Promise in Tough to Treat Lung Cancer

Amgen’s bispecific T-cell engager is showing promise for small cell lung cancer. The California biopharma company reported positive Phase II results for tarlatamab Friday, coinciding with a data presentation at the European Society for Medical Oncology Congress 2023 and publication in The New England Journal of Medicine.